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Abstract G protein-coupled receptors (GPCRs) are a major
drug target and can be activated by a range of stimuli, from
photons to proteins. Despite the progress made in the last
decade in molecular and structural biology, their exact
activation mechanism is still unknown. Here we describe
new insights in specific regions essential in adenosine A2B
receptor activation (A2BR), a typical class A GPCR. We
applied unbiased random mutagenesis on the middle part of
the human adenosine A2BR, consisting of transmembrane
domains 4 and 5 (TM4 and TM5) linked by extracellular
loop 2 (EL2), and subsequently screened in a medium-
throughput manner for gain-of-function and constitutively
active mutants. For that purpose, we used a genetically
engineered yeast strain (Saccharomyces cerevisiae
MMY24) with growth as a read-out parameter. From the
random mutagenesis screen, 12 different mutant receptors
were identified that form three distinct clusters; at the top of
TM4, in a cysteine-rich region in EL2, and at the
intracellular side of TM5. All mutant receptors show a vast
increase in agonist potency and most also displayed a
significant increase in constitutive activity. None of these
residues are supposedly involved in ligand binding directly.
As a consequence, it appears that disrupting the relatively
“silent” configuration of the wild-type receptor in each of the
three clusters readily causes spontaneous receptor activity.
Keywords G protein-coupled receptor.Constitutive
activity.Adenosine A2B receptor.S. cerevisiae.Random
mutagenesis
Introduction
The adenosine receptors form a small subfamily of class A
G protein-coupled receptors (GPCRs). Four subtypes of
adenosine receptors are known (A1 receptor (A1R), A2A
receptor (A2AR), A2B receptor (A2BR), and A3 receptor
(A3R)) that all bind the endogenous ligand adenosine. The
A1R and the A3R subtypes are coupled to Gi proteins,
hereby mediating the inhibition of adenylyl cyclase causing
decreased levels of cAMP in the cell. The A2AR and A2BR
signal mainly through Gs proteins resulting in the activation
of adenylyl cyclase and an increase in intracellular cAMP
levels. Of the adenosine subfamily, the A2BR subtype has
been investigated least. Similar to all GPCRs, the adenosine
A2BR is made up of seven transmembrane domains
connected by three intracellular and three extracellular
loops, an extracellular N terminus, and an intracellular C
terminus. The A2BR has been implicated in several (auto)-
immune diseases such as asthma and chronic obstructive
pulmonary disease and is, therefore, an interesting drug
target [1].
In a previous study, random mutagenesis combined with
a yeast screen for activating mutant receptors have been
performed on two parts of the adenosine A2BR in order to
identify specific residues involved in the activation of the
receptor [2, 3]. Mutations were randomly introduced in two
separate fragments of the receptor, one ranging from the
ATG until a KpnI restriction site in the second intracellular
loop and a second form the BglII restriction site in the third
intracellular loop until the end of the receptor (Fig. 1).
These studies revealed many constitutively active muta-
tions, both in the transmembrane domains as well as in the
extracellular regions. The fragment that is in between the
two restriction sites KpnI and BglII, encompassing trans-
membrane domain 4 (TM4), the second extracellular loop 2
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been examined. However, this region may be very
important in the activation mechanism of the receptor. All
three domains in this fragment have been implied to
participate in the dynamic movements the receptor under-
goes during activation [4]. Clear evidence for the impor-
tance of this region is also provided by the recently
published crystal structures of both the antagonist- and
agonist-bound adenosine A2AR, the closest homologue of
the A2BR. In particular, EL2 and TM5 appear to be
involved directly in ligand binding and in conformational
movements induced by agonist binding [5–7]. Also, EL2
has been proposed to act as a negative regulator for the
receptor, keeping it in its inactive state and is in many
receptors part of the ligand binding site [8–11].
In the present study, we examined the influence of EL2
and its two adjacent transmembrane domains, TM4 and
TM5, of the adenosine A2BR is made up of seven on
receptor activation. We performed an unbiased random
mutagenesis screen for gain-of-function mutations as well
as constitutively active mutants (CAMs), i.e., mutant
receptors that show basal activity independent of an
Fig. 1 Snake plot of the adenosine A2BR. Mutated residues within the
A2BR identified to result in increased constitutive activity are
indicated in gray. These mutations originate from two previously
described screens [2, 3] and the TM4-EL2-TM5 screen described in
the current paper. The putative disulfide bridges are indicated with
dotted lines. The disulfide bridge conserved in many class A GPCRs
links C78
3.25 and C171
EL2. The non-conserved second disulfide
bridge between EL1 and EL2 is based on an analogous bond in the
crystal structures of the adenosine A2AR (PDB: 3EML, 3QAK,
3YDO, and 3YDV); it links C72
EL1 and C167
EL2. The restriction
sites KpnI and BglII are indicated; they were used to obtain the
fragment for random mutagenesis
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inactive (R) and active conformation (R*) is shifted, so
that the active state is energetically more favorable than in
the wild-type situation, similar to what occurs when the
receptor binds an agonist [12]. Residues that are mutated to
cause this shift in equilibrium are therefore likely to be
involved in the on-and-off switch of the receptor and can
provide us with information on the activation mechanism of
the receptor.
We performed the screen for activating mutant receptors
using a Saccharomyces cerevisiae strain that has been
genetically modified to serve as a reporter system with
growth as an output parameter. This yeast system is an ideal
background to monitor activation of a single GPCR since
the endogenous GPCR (Ste2) has been removed from the
system while still maintaining the complete GPCR signal-
ing machinery [13]. Several previous reports have proved
this eukaryotic system to be predictive of the mammalian
situation, as shown by functional and binding studies in
CHO cells [2, 14]. Several mutated residues were identi-
fied, causing the receptor to be highly increased in both
agonist-induced and spontaneous activity. The results
presented here can be of general interest in increasing our
understanding of the activation mechanism of class A
GPCRs, of adenosine receptors in particular as well as other
members of this superfamily.
Materials and methods
DNA constructs
The S. cerevisiae expression vector containing the adeno-
sine A2BR gene, the pDT-PGK_A2BR plasmid, was kindly
provided by Dr. Simon Dowell from GSK (Stevenage, UK).
A KpnI restriction site was introduced in the A2BR gene in
the region encoding the second intracellular loop. Together
with a restriction site in the third intracellular loop, BglII, it
is possible to divide the receptor into three large fragments
suitable for random mutagenesis. The fragment between
these two restriction sites was used in the mutagenic PCR.
This fragment encodes transmembrane domain four, the
second extracellular loop, and transmembrane domain five
(TM4-EL2-TM5).
Mutagenic PCR for the construction of the random
mutagenesis library
The introduction of random mutations in the adenosine
A2BR was achieved by manipulating the polymerase chain
reaction adapted from the method of Fromant et al. [15]. In
this error-prone PCR method, the balance between Mg
2+
ions and Mn
2+ ions was shifted, compromising fidelity of
the DNA polymerase enzyme. Furthermore, the introduc-
tion of mutations can be guided by adding excess of one of
the nucleotides (the “forcing” nucleotide). This technique
makes it possible to introduce mutations in fragments of up
to 400 bp in length. The DNA fragment encoding TM4-
EL2-TM5 encompasses 262 bp.
The mutagenic reaction contained 10 ng of template
DNA, 0.1 μM concentrations of each primer, 0.2 mM
concentrations of dNTPs as well as 3.4 mM concentrations
of the nucleotide in excess dCTP, 0.5 mM MnCl2,4 . 7m M
MgCl2, and 0.5 units of Super Taq polymerase without
proofreading. The number of mutagenic PCR cycles was
set to 10. Using these conditions, only a limited amount of
mutations are introduced per fragment [16].
The following primers were used:
5′-GGTATAAAAGTTTGGTCACGGGTACCCGAG
CAA-3′
5′-GAAGCTGCCTGCAGGCCACCAGGAAGATCT
TAATG-3′
The mutagenic PCR products were submitted to agarose
gel electrophoresis and the gel bands containing the mutated
fragments were isolated from the gel and purified. Subse-
quently,themutatedfragmentswereamplifiedfurtherwithten
cycles of a regular PCR with the same primer sets. After the
error-prone PCR, the normal fragment TM4-EL2-TM5 in the
wild-type receptor was replaced by the mutated fragments
using the restriction sites KpnI and BglII and transformed into
DH5α Escherichia coli-competent cells (Invitrogen, San
Diego, CA, USA). Plasmids were isolated from the culture
resulting in a mutagenic adenosine A2BRl i b r a r y .
Transformation in MMY24 S. cerevisiae strain
pDT-PGK_A2BR plasmids were transformed into an S.
cerevisiae yeast strain according to the Lithium-Acetate
procedure [17]. The MMY24 strain is derived from the
MMY11 strain and was further adapted to communicate
with mammalian GPCRs through the introduction of a
chimeric G protein [13]. The genotype of the MMY24
strain is: MATahis3 leu2 trp1 ura3can1 gpa1_::G_i3 far1 ::
ura3 sst2_::ura3 Fus1::FUS1-HIS3 LEU2::FUS1-lacZ
ste2_::G418R. To measure signaling of GPCRs, the
pheromone signaling pathway of this strain was coupled
via the FUS1 promoter to HIS3, a gene encoding the key
enzyme in histidine production, imidazole glycerol-
phosphate dehydrase. The degree of receptor activation
was measured by the growth rate of the yeast on histidine-
deficient medium. A second reporter gene was placed under
control of the FUS1 promoter; the LacZ gene. Transcription
of this gene results in the production of the enzyme β-
galactosidase. The presence of this enzyme is also a
measure of receptor activation.
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The random mutagenesis screen was performed on selec-
tion agar medium in two steps. Firstly, yeast cells were
selected for the presence of the plasmid pDT-PGK using
selection medium lacking the markers uracil and leucine.
After 3 days of incubation at 30°C, positive colonies were
pooled. For the second selection step, 10
4 cells were spread
onto selection medium lacking uracil, leucine, and histidine
(YNB-ULH) to select for the MMY24 yeast strain, the pDT-
PGK plasmid, and activity of the receptor, respectively. A
concentration of 7 mM 3-aminotriazole (3-AT), a compet-
itive inhibitor of imidazole glycerol-phosphate dehydrase,
was added to the agar plates to suppress basal yeast
growth that occurs in histidine-deficient medium. Also, a
concentration of 1 nM of the full A2BR agonist 5′-N-
ethylcarboxamidoadenosine (NECA) was added to the
medium, a concentration at which yeast cells expressing
the wild-type human adenosine A2BR still barely grow.
After 3 days, colonies were selected and transferred to
new selection plates. To further select for true active
mutant receptors, we performed a qualitative β-
galactosidase assay according to protocol #PT3024-1 from
Clontech (Clontech Laboratories, Mountain View, CA,
USA). In brief, yeast colonies w e r et r a n s f e r r e dt oaf i l t e r
and lysed using repeated freeze-thawing with liquid
nitrogen. The filter was then placed on top of several
Whatman papers presoaked in Z-buffer (16.1 g/L
Na2HPO4,5 . 5g / LN a H 2PO4,0 . 7 5g / LK C l ,0 . 2 4 6g / L
MgSO4, and 0.3% β-mercaptoethanol) and 0.3 mg/ml X-gal
(5-bromo-4-chloro-3-indolyl-β-D-galactosidase), a substrate
of β-galactosidase. The filter was incubated at 30°C until a
blue color appeared. Colonies with a blue color were chosen
for further characterization. Mutated receptors were se-
quenced and subsequently retransformed into the yeast strain
to confirm their activated phenotype.
Liquid growth assay
To characterize the mutant receptors further, concentration-
growth curves were generated in a liquid growth assay. This
assay is on 96-wells scale and growth is easily determined
by measuring absorption at a wavelength of 595 nm. In
this assay, 150 μl liquid YNB-ULH medium with 7 mM
3-AT and a varying concentration of NECA (10
−10–
10
−5 M) was added to each well. A concentration range
from 10
−10 to 10
−5 M was also used for the concentration-
growth curves with BAY 60-6583 (2-[6-amino-3,5-
dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-
ylsulfanyl]acetamide; synthesized in house), a non-
nucleoside agonist [18]. Yeast cells from an overnight
culture were diluted to around four·10
6 cells/ml (OD600≈
0.2) and 50 μl was added per well. The 96-well plate was
then incubated for 35 h in a Genios plate reader (Tecan,
Durham, NC, USA) at 30°C, keeping the cells in
suspension by shaking every 10 min at 300 rpm for
1 min. Results originate from three independent experiments,
performed in duplicate.
Solid growth assay
To monitor the response of the mutant receptors in the
presence of the inverse agonist ZM241385 (4-{2-[7-amino-
2-(2-furyl)[1,2,4]triazolo-[2,3-a][1,3,5]triazin-5-yl-amino]
ethyl}phenol), a solid yeast growth assay was used. Yeast
growth was determined based on growth density, rather
than absorption at 595 nm; this enabled us to visualize the
level of constitutive activity more clearly. In the solid
growth assay, yeast cells from an overnight culture were
diluted to around 400,000 cells/ml (OD600≈0.02), and
droplets of 1.5 μl were spotted on selection agar plates,
YNB-ULH, containing 7 mM 3-AT and a ZM241385
concentration ranging from 10
−11 to 10
−5 M. For the
single-point experiments, a final concentration of 10
−5 M
ZM241385 was used [19]. After incubation at 30°C for
50 h, the plates were scanned and receptor-mediated yeast
growth was quantified with Quantity One imaging software
from Bio-Rad (Hercules, CA, USA). The growth rate of
yeast was calculated as the density of each spot with a
correction for local background on the plate. Results are
obtained from four independent experiments, performed in
quadruplicate.
Whole cell radioligand binding experiments
Yeast cells expressing wild-type or mutated A2BRs were
cultured overnight in rich YAPD (Yeast Extract Adenine
Peptone Dextrose) medium. Cells were centrifuged for 5 min
at 2,000×g, the pelleted cells were once washed with 0.9%
NaCl. The cells were again centrifuged 5 min at 2,000×g
and diluted in the assay buffer (50 mM Tris–HCl pH7.4+
1 mM EDTA) to OD600=40 (OD600=1≈2.5·10
7 cells/ml).
Binding experiments were performed with 1.3 nM [
3H]PSB-
603 (8-[4-[4-(4-chlorophenyl)piperazine-1-sulfonyl)phenyl]]-
1-propylxanthine; KD, yeast=0.8±0.02 nM) and a final cell
concentration of 25·10
7 cells/ml in a total volume of 100 μl
[3, 20]. Nonspecific binding was determined in the presence
of 1 mM NECA. For whole competition curves, a
concentration range of 10
−10–10
−3 M of the ribose agonist
NECA, 10
−10–10
−4 M of the non-ribose agonist BAY 60-
6583, or 10
−10–10
−4 M of the inverse agonist ZM241385
was used. Samples were incubated for 1 h at 25°C while
shaking vigorously to keep the yeast cells in suspension.
Incubation was terminated by adding 1-ml ice-cold assay
buffer. Bound from free radioligand was immediately
separated by rapid filtration through Whatman GF/B filters
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manifold during which the filters were washed six times with
ice-cold assay buffer. Filter-bound radioactivity was deter-
mined by scintillation spectrometry (Tri-Carb 2900TR;
PerkinElmer Life and Analytical Sciences) after addition
of 3.5 ml of PerkinElmer Emulsifier Safe. Results are
obtained from three independent experiments, performed
in duplicate.
Whole cell extracts and immunoblotting
Whole protein cell extracts were made from the trans-
formed yeast cells using trichloroacetic acid (TCA). From
an overnight culture, 1.2·10
8 yeast cells were harvested in
mid-log phase. The cells were washed twice with 20% TCA
after which they were broken by vigorous vortexing in the
presence of glass beads. The yeast cell extracts were
separated using SDS/PAGE and subsequently blotted on
Hybond-ECL membranes. For this purpose, a sample of
4.0 μl containing 12 μg protein was loaded on a 12.5%
SDS/PAGE gel. A semi-automated electrophoresis tech-
nique (PhastSystem™, Amersham Pharmacia Biotech) was
used for SDS/PAGE as well as blotting. The antibody
directed against the C-terminal region of the adenosine
A2BR was kindly provided by Dr. I. Feoktistov (Vanderbilt
University, Nashville). Densitometric analysis of the
protein bands was performed using the volume analysis
tool as present in the Quantity One imaging software
from Bio-Rad (Hercules, CA, USA). The nonspecific
band at approximately 45 kDa was used as loading
control. The ratio between specific A2BR protein bands
(at 29 and 48 kDa) and the nonspecific band was
determined and the wild-type receptor was set at 100%,
the empty vector pDT-PGK at 0%. The experiment was
performed in duplicate. The relative expression levels
represent expression of the whole receptor population, not
distinguishing between cell surface and intracellularly
expressed protein
Bioinformatics—mapping the mutated residues
onto the adenosine A2AR structure
The positions of the mutations identified in the random
mutagenesis screen were mapped onto the corresponding
positions in the crystal structure of the agonist-bound
adenosine A2AR (PDB: 2YDV) [7]. These corresponding
positions were determined by a multiple sequence align-
ment created using ClustalW with default parameters. To
make use of known crystallographic data, the sequences of
the CXCR4 chemokine receptor (CXCR4R) and the β2-
adrenergic (b2AR) receptor were included in this align-
ment. The EL2 was defined from the crystal structures of
the A2AR (residues, 143–173), the CXCR4R (residues,
175–192), and the b2AR (residues, 171–196). The amino
acids in the TM domains of the various receptors were
related through their Ballesteros and Weinstein numbering
[21].
Bioinformatics—cysteine occurrence analysis
To gain insight in the number of class A GPCRs that have
multiple cysteines present in the second extracellular loop,
we analyzed all human olfactory (415) and non-olfactory
(221) class A GPCRs as present in the GPCRDB [22]. A
cysteine count was performed on the second extracellular
loop that for this analysis was defined as the fragment
between residues 4.55 and 5.38 according to the Ballesteros
and Weinstein numbering [21]. These two residues are
located at the interface of the loop and the transmembrane
domains but are present within the membrane in all
predictions.
Results
Random mutagenesis screen in yeast
Mutations were randomly introduced in the fragment
encoding for TM4, the EL2, and TM5 of the human
adenosine A2BR using an error-prone PCR reaction (Figs. 1
and 2). The corresponding fragment in the wild-type
receptor was replaced after mutagenesis by the mutated
fragments, which rendered a set of approximately 5,000
different plasmids of which ca. 80% contained mutations.
The mutations occurred in a low frequency; most of the
mutant receptors contained single-point mutations and the
mutant receptor with the highest mutation frequency
contained five nucleotide changes. These results are
comparable to a random mutagenic library of the first three
transmembrane domains of the A2BR published by Beukers
et al. [2]. After ligation, the plasmids were propagated in
competent E. coli cells, resulting in the final mutant A2BR
library (Fig. 2). This mutant library was subsequently
t r a n s f o r m e di nt h eS. cerevisiae MMY24 strain. The
MMY24 yeast strain has been genetically modified to
enable mammalian GPCRs to couple to the yeast phero-
mone pathway with subsequent transcription of the reporter
gene HIS3, increasing the histidine synthesis. We used this
trait to specifically select yeast cells that express an active
receptor by their ability to produce histidine and therefore
grow on histidine-deficient medium. Before starting the
actual screen, we first selected yeast cells that were
successfully transformed. We then screened the transformed
MMY24 cells for an active phenotype on selection plates
lacking YNB-ULH to select for the MMY24 yeast strain,
the pDT-PGK plasmid, and activity of the receptor,
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the agonist NECA (EC50 value at wild-type A2BR: 137±
10 nM, see also Table 1), we screened for both CAMs and
mutant receptors with increased agonist potency. In total,
ca. 0.5 million yeast clones were used for the final
activation screen, so the library was screened approximately
100 times. From the screen, all well separated colonies that
appeared on the selection plates were selected (a total of
148 yeast colonies).
Besides the reporter gene HIS, a second reporter gene
was incorporated into the MMY24 genome under the same
promoter; the LacZ reporter gene, causing the yeast cell to
also produce the enzyme β-galactosidase. To proceed with
the most active mutant receptors, we performed a qualita-
tive β-galactosidase assay. The colonies were lysed and the
presence of the enzyme β-galactosidase was measured. The
35 colonies with the strongest response in this assay, out of
the original 148, were selected, plasmids were isolated from
the yeast cells, and the mutations were identified by
sequencing. Several of the nucleotide changes observed in
the sequences resulted in the same amino acid changes in
the A2BR. Mutant receptor G135A
4.55/I197L
5.53/Y202N
5.58
was identified most, namely 12 times out of the 35
sequenced plasmids (shown in superscript are the positions
according to the Ballesteros and Weinstein GPCR numbering
system [21]) (Fig. 2; Table 1).
In total, 12 different mutant receptors were identified,
containing altogether 13 mutated positions (Fig. 1). Among
the 12 mutant receptors, residues F141
4.61, C167
EL2, and
Y202
5.58 were found to be mutated more than once. Amino
acid changes of F141
4.61 were identified in two different
receptors; in the single mutant F141L
4.61 and in the double
mutant F141C
4.61/Y202C
5.58. The mutation C167S
EL2 was
found as a single mutant as well in combination with a
residue outside of the cluster: T155
EL2. Mutations at
position Y202
5.58 were present in three different mutant
receptors: G135A
4.55/I197L
5.53/Y202N
5.58, F141C
4,61/
Y202C
5.58, and Y202S
5.58 (Table 1).
The mutated residues form three distinct clusters in the
receptor; at the top of TM4, at a cysteine-rich area in EL2,
and at the bottom of TM5. Four receptors contained
mutations in TM4, forming a small cluster of three amino
acids: G135
4.55, I36
4.56, and F141
4.61. In EL2, a total of
seven residues were found mutated in five different mutant
receptors. Five of the seven residues form a tight cluster,
namely C166
EL2,C 1 6 7
EL2,L 1 6 8
EL2, V169
EL2,a n d
F173
EL2. The cluster seen in TM5 consists of three
residues: I197
5.53, V200
5.56, and Y202
5.58 (Fig. 1; Table 1).
Fig. 2 Schematic overview of
the screen for activating muta-
tions. The mutated fragments
from the mutagenic PCR were
reintroduced in an otherwise
wild-type A2BR in the pDT-PGK
vector, resulting in the muta-
genic A2BR library. The library
was transformed in the MMY24
yeast strain and screened for
mutant receptors with constitu-
tive activity and/or an increased
potency for NECA. As a second
selection criterion, the presence
of β-galactosidase was deter-
mined in a qualitative assay,
resulting in a final selection of
35 yeast colonies. Sequencing
revealed 12 different
mutant receptors
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To confirm the active phenotype, all 12 receptors were
retransformed into the yeast strain and their pharmacology
was investigated using yeast growth assays. All mutant
receptors showed an increase in constitutive activity,
although less pronounced in mutant receptors F141L
4.61
and I136T
4.45 (1.5 times compared with wild type) (Fig. 3a;
Table 1). Mutant receptor G135A
4.55/I197L
5.53/Y202N
5.58
showed the largest increase in basal activity with yeast
Table 1 Characterization of the adenosine receptor A2B receptor mutants identified from the random mutagenesis screen using the liquid yeast
growth assay
a
b
Mutations are shown in the numbering of the A2BR protein as well as according to the Ballesteros and Weinstein GPCR numbering system (in
superscript). EC50 values (nM) are shown as means±SEM of at least three independent experiments, each performed in duplicate. Results with the
ribose agonist NECA are shown for all mutant receptors. For wild-type and mutant receptors F141L
4.61, C167S
EL2, and Y202S
5.58 also results
with the non-ribose agonist BAY 60-6583 are shown. Results of two-tailed t test comparing EC50 value of mutants with EC50 value of WT
*p<0.001; **p<0.01
aThe relative increase in growth compared with wild type when no agonist was present
bThe intrinsic activity of the receptor, where the maximal growth level of wild-type receptor in response to the agonists was set as 100%
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the maximal activation level. The constitutive activity of this
mutant receptor could be reduced by the inverse agonist
ZM241385, however, a residual activity of 8% remained. The
level of constitutive activity of the other 11 mutant receptors
could be fully suppressed (Fig. 3a). For mutant Y202S
5.58,a
full concentration-growth inhibition curve with ZM241385
showed a potency of 31.3±4.4 nM for ZM241385. In
comparison, in literature values between 13 and 50 nM have
been reported for wild-type A2BR[ 23, 24]( F i g .3b).
Concentration-growth curves revealed that all mutant
receptors showed a large increase in potency of more than
one log-unit for the full agonist NECA (Table 1). Curves of
mutant receptors F141L
4.61, C167S
EL2, Y202S
5.58,
G135A
4.55/I197L
5.53/Y202N
5.58, and T155A
EL2/C167S
EL2
are shown in Fig. 4. Even though the level of constitutive
activity in mutant G135A
4.55/I197L
5.53/Y202N
5.58 was very
high, the maximal level of receptor activation could be
reached in response to NECA in a dose-dependent manner,
with an EC50 value of 7.1±0.7 nM compared with 137±
10 nM seen for wild-type A2BR( T a b l e1). Mutant receptor
Y202S
5.58 also has a relatively high level of constitutive
activity being 13-fold higher than wild-type receptor.
However, upon stimulation with NECA the maximum
receptor activation (Emax) was lower than observed with
wild-type A2BR. Similar results were observed for the
receptor where Y202
5.58 was mutated in combination with
residueF141:mutantreceptorF141C
4.61/Y202C
5.58 (Table 1).
Residues F141
4.61 (TM4), C167
EL2 (EL2), and Y202
5.58
(TM5) were identified multiple times in the screen,
suggesting a particular important function of these positions
in receptor activation. For additional studies, we therefore
focused on the single mutant receptors containing each of
the residues; F141L
4.61, C167S
EL2, and Y202S
5.58. These
single mutants were also studied with BAY 60-6583, a
structurally different A2BR agonist [18]. This full agonist
lacks a ribose moiety that is present in the adenosine
derivative NECA and previously thought to be essential for
adenosine receptor activation. The chemical structures of
both agonists NECA and BAY 60-6583 are shown in
Tables 1 and 2. BAY 60-6583 was more than five times
Fig. 4 Concentration-response curves from liquid yeast growth
experiments. Curves are shown of wild-type (filled squares) and
mutant receptors F141L
4.61 (filled triangles), C167S
EL2(inverted filled
triangles), Y202S
5.58 (filled circles), G135A
4.55/I197L
5.53/
Y202N
5.58(filled diamonds), and T155A
EL2/C167S
EL2 (empty circles).
Curves are shown from a representative experiment. Data for all
experiments are presented in Table 1
Fig. 3 Constitutive activity of the mutant receptors determined in a
solid yeast growth assay. a Growth was measured on selective agar
plates YNB-ULH in the absence of a ligand or in the presence of
10 μM of the inverse agonist ZM241385. The vertical bars in the
graph represent the percentage spontaneous activity of wild-type
A2BR and mutant receptors (black) and the response to ZM241385
(white). The maximal activation level of the wild-type receptor was set
at 100%; the background of the selection plate was set at 0%. b
Concentration-growth inhibition curve of mutant receptor Y202S
5.58.
A concentration range of 10
−11–10
−5 M ZM241385 was added to the
selection agar plates. The figure is representative of one experiment
performed in quadruplicate. The IC50 value for ZM241385 was 31.3±
4.4 nM, determined from four independent experiments
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4.61; in comparison,
NECA’s potency was more than 25-fold increased. Both
NECA and BAY 60-6583 displayed a 10-fold increase in
potency on mutant Y202S
5.58. Mutant receptor C167S
EL2
showed a small 2-fold increase in potency in response to
BAY 60-6583, with NECA this was over 15-fold.
Western blot analysis of whole cell lysates showed a
similar degree of expression of the mutant receptors
compared with the wild-type receptor, indicating that the
increase in activation profile was not due to overall
increases in receptor levels in the system, both intracellular
and expressed at the cell surface. Results of mutant
receptors F141L
4.61, C167S
EL2, and Y202S
5.58 are shown
in Fig. 5.
Radioligand binding experiments on the activated mutant
receptors
To investigate the influence of the mutated residues on
b i n d i n gn e x tt oa c t i v a t i o n ,we performed radioligand
binding experiments using the A2BR selective antagonist
[
3H]PSB-603 [3, 20]. Saturation binding experiments
showed a KD of the radioligand on whole yeast cells
expressing the hA2BR of 0.81±0.02 nM (data not shown),
in comparison, the KD value determined on CHO cell
membranes expressing the hA2BR was 0.40±0.19 nM [20].
Competition binding curves were made for wild-type and
mutant receptors with unlabeled NECA, BAY 60-6583, or
ZM241385 as a displacer. For mutant receptor Y202S
5.58,
we were not able to reach a high enough window to
Fig. 5 Western blot analysis. The relative expression of mutants
F141L
4.61, C167S
EL2, and Y202S
5.58 compared with the wild-type
receptor was determined using densitometric analysis of the Western
blots. The ratio was determined between the density of the specific
bands and the density of the nonspecific band that is always present on
the blot. Wild-type receptor was set at 100%; the empty vector pDT-
PGK was set at 0%. The experiment was performed in duplicate. One
representative blot is shown in the upper panel. The arrows indicate
the specific A2BR bands; these are located at ca. 29 and 48 kDa
Table 2 Competition binding experiments with the radiolabeled antagonist [
3H]PSB-603 (KD,yeast=0.8±0.02 nM)
WT receptor and mutants F141L
4.61 and C167S
EL2 were tested on their affinity for the full agonist NECA, the non-ribose agonist BAY 60-6583,
and the inverse agonist ZM241385. IC50 values are shown as means±SEM of at least three independent experiments, each performed in duplicate.
Results of two-tailed t test comparing IC50 value of mutants with IC50 value of WT
ns not significant
*p<0.05; **p<0.01
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decrease in affinity for the radiolabeled antagonist [
3H]
PSB-603 since no change in expression levels was
observed (Fig. 5). Mutant receptors F141L
4.61 and
C167S
EL2 showed a large increase in NECA affinity
compared with the wild-type receptor of 13- and 9-fold,
respectively (Table 2). In the radioligand binding experi-
ment with BAY 60-6583 as displacer, the affinity of mutant
F141L
4.61 was again increased. In contrast, mutant
C167S
EL2 had an affinity for BAY 60-6583 similar to
wild-type A2BR (Fig. 6; Table 2). The affinity of the inverse
agonist ZM241385 was also determined. Both mutant
receptors did not show a large change in affinity for
ZM241385 compared with the wild-type receptor, although
the effect on F141L
4.61 was significant (Table 2).
Bioinformatic analyses
Recently, several crystal structures of the adenosine A2AR
have been elucidated (PDB entry codes: 3EML, 3QAK,
2YDO, 2YDV) [5–7]. The adenosine A2AR is the closest
homologue of the adenosine A2BR, with 82.1% amino acid
similarity and 59.4% identity. We mapped the mutated
residues onto the crystal structure of the active A2AR
structure bound to NECA (PDB: 2YDV) in order to obtain
a view on the 3D localization of the residues (Fig. 7). The
corresponding positions of the mutated A2BR residues in
the A2AR sequence were determined by a multiple
sequence alignment (Fig. 7a). To improve the quality of
the multiple sequence alignment and to determine the
transition between loop and transmembrane domains, we
also included sequences of two other crystallized GPCRs;
the b2AR receptor and the CXCR4R receptor [25, 26]. Also
in the 3D view, clusters of mutations can be observed in the
top of TM4 and the bottom of TM5 (Fig. 7a). The
corresponding positions of the cluster in EL2 appear to
reside in a part of the loop that is involved in forming an
anti-parallel β-sheet with EL1. It is very likely that this
typical protein structure is also present in the A2BR and
constitutively active mutations in the putative beta-strand in
EL1 of this receptor have previously been described by our
laboratory [3].
In the A2AR structure, all three available cysteines in the
second extracellular loop are involved in bridge formation.
It has been proposed that formation of extracellular
disulfide bridges may be an important general mechanism
for regulating the activity of GPCRs [27]. The adenosine
A2BR has a high number of cysteines in EL2 that could all
potentially form extracellular disulfide bridges. A previous
sequence alignment analysis performed by de Graaf et al.
already revealed that over 90% of class A GPCRs contain
at least one cysteine in EL2 and that several receptors
contain more. In most cases, the most downstream cysteine
appeared involved in forming the conserved disulfide
bridge with TM3 [28]. To investigate how common
multiple cysteines are in class A GPCRs, we performed a
cysteine occurrence analysis. We counted the number of
cysteines present between residues 4.55 and 5.38 [21], a
region that encompasses the second extracellular loop. The
majority of non-olfactory receptors contains only one
cysteine within EL2 (Fig. 8a); this cysteine represents in
most cases the conserved cysteine present in over 90% of
class A GPCRs. From what is known from the currently
available crystal structures this conserved cysteine forms a
disulfide bridge with a cysteine present in the top of TM3
that is essential for receptor structure and function. The
adenosine A2BR is the only receptor with four cysteines in
EL2, which is the highest cysteine count in this analysis.
The adenosine A2AR, the closest homologue of the A2BR,
contains one cysteine less with three cysteines in the loop.
The other adenosine receptor subtypes, the A1R and A3R,
only hold one cysteine in EL2. In EL2 of olfactory
receptors, generally multiple cysteines are present; ca.
80% of the receptors contain three cysteines in the loop
Fig. 6 Competition binding curves using [
3H]PSB-603. Displacement
curves of wild type A2BR( filled squares), mutant receptor F141L
4.61
(inverted filled triangles) and mutant receptor C167S
EL2 (filled
triangles) with the ribose agonist NECA (a) and the non-ribose
agonist BAY 60-6583 (b). The graphs are the combined result of three
independent experiments performed in duplicate
32 Purinergic Signalling (2012) 8:23–38Fig. 7 Mutated residues of the
A2BR mapped on the crystal
structure of the A2AR. a Multi-
ple sequence alignment with all
four adenosine receptor sub-
types (A2AR, A2BR, A1R, and
A3R) as well as the sequences of
two other crystal structures of
CXCR4 and the b2AR to ensure
the most plausible definition of
EL2. The mutated residues are
indicated in bold font and
underlined. b Based on the
multiple sequence alignment,
the mutated residues identified
in the random mutagenesis
screen were mapped onto the
crystal structure of the A2AR
(PDB: 2YDV; blue), the closest
homologue of the A2BR. The
corresponding mutated residues
and their side-chains are indi-
cated in magenta. The
ribbon representation also shows
the co-crystallized ligand NECA
as well as the three disulfide
bridges that restrict EL2 in
the A2AR
Fig. 8 Cysteine occurrence analysis. The number of cysteines present
in the second extracellular loop was counted in human class A
GPCRS. For this analysis, the loop was defined between residues 4.55
(TM4) and 5.38 (TM5). The graphs represent all human class A
GPCRs, either non-olfactory (a) or olfactory (b), as present in the
GPCRDB (http://www.gpcr.org/7tm/), with the x-axis the number of
cysteines counted in EL2. The majority of non-olfactory receptors
contains one cysteine in EL2; the adenosine A2BR alone is responsible
for the bar at four cysteines. Most olfactory receptors have three
cysteines in the loop
Purinergic Signalling (2012) 8:23–38 33(Fig. 8b). This special subfamily of class A GPCRs is
responsible for our sense of smell by binding odorants.
Metal ions, such as zinc, have been proposed to be essential
in recognition and binding of odorants to their receptor, in
which ligation of the metal ion to the thiol group of
cysteine residues might play an important role [29].
Discussion
A random mutagenesis screen for gain-of-function and
CAMs was performed on fragment TM4-EL2-TM5 of the
human adenosine A2BR. These three regions of the receptor
have been implied to participate in the dynamic movements
the receptor undergoes during activation. Upon receptor
activation, a coupling between movements of EL2 and
TM5 has been observed as well as a rearrangement in the
hydrogen-bonding networks connecting EL2 with the
extracellular ends of TM4, TM5 and TM6 [4].
For the β1-adrenergic receptor, the β2-adrenergic receptor,
(rhod)opsin, and the adenosine A2AR, we now have access to
crystal structures of both inactive and active conformations
[5–7, 30–35]. These structures reveal that in the transition
between the inactive and the active conformation subtle
changes at the extracellular surface and the ligand binding
site lead to large movements at the intracellular surface. The
lower regions of TM5 and TM6 show a particularly large
displacement that is allowed by the presence of conserved
prolines (5.50 and 6.50) that interrupt the hydrogen bond
network within the helices.
From the screen, 12 different mutant receptors were
identified. Most of these mutants show a significant
increase in constitutive activity, with mutant G135A
4.55/
I197L
5.53/Y202N
5.58 even reaching a basal activity that is
over 60% of the maximal activation level (Fig. 3). All
mutant receptors displayed a very large increase in potency
for NECA compared with wild type, ranging from an
improvement in activation of 11-fold (V200G
5.56) to even
25-fold (F141L
4.61) (Table 1). That we were able to identify
mutant receptors with such large effects on activation
further emphasizes the strength of using an unbiased
random mutagenesis approach in combination with the S.
cerevisiae system.
Three “hotspots” important for A2BR activation
The residues found mutated in our screen are located in
three distinct clusters: at the top of TM4, in a cysteine-rich
region in EL2, and at the bottom half of TM5 (Figs. 1 and
7b). Even though a number of mutant receptors contain
multiple amino acid changes, no combinations between
mutations in EL2 and the transmembrane domains were
identified. This suggests that the influence of EL2 on
receptor activation is at a different level than that of the
transmembrane domains. There is accumulating evidence
that agonist binding and activation occur through a series of
conformational intermediates, for which multiple switches
are needed to be activated [36, 37]. It is quite likely that the
first switch is present at the site of ligand entry to the
receptor, i.e., at the extracellular surface.
The cluster in TM4 consists of three amino acids;
G135
4.55, I136
4.56, and F141
4.61. A saturated mutagenesis
screen performed on the transmembrane domains of the
complement factor 5a receptor, also revealed important
residues at the extracellular membrane interface of TM4,
corresponding to positions 4.46, 4.53, 4.55, 4.57, 4.58, and
4.60 [38, 39]. Very recently, Warne et al. published four
structures of the β1-adrenergic receptor bound to full and
partial agonists. One difference between an antagonist and a
full agonist-bound β1-adrenergic receptor is that a van der
Waals interaction is broken between positions 4.56 and
5.46. This results in a reduced interface between helix 4 and
5 that may be significant in the activation process [30]. In
the inactive structure of the adenosine A2AR (PDB/3EML),
a similar van der Waals interaction exists between I135
4.56
and C185
5.46. Also, a hydrogen bond is formed between
Q89
3.37 and the backbone of C185
5.46 [5]. In the active
structures of the A2AR (PDB: 3YDO/3YDV/3QAK), the
cysteine side chain shifts and the hydrogen bond is broken
[6, 7]. Noteworthy is that in the 3YDO and 3YDV
structures bound to adenosine and NECA, respectively,
position 3.37 was mutated (Q89A) [7].
The mutations found mutated in EL2 are located in a
cysteine-rich region of the loop that may be involved in a
β-strand structure in the loop as is seen in the structure of
the A2AR (Fig. 7b). The partnering strand in EL1 that is
involved in forming the β-sheet with EL2 has previously
been reported to be essential in A2BR activation [3]. EL2
has been suggested to act as a negative regulator that keeps
the receptor in a silent state before agonist-induced
activation [8–10]. The mutant receptors in EL2 that we
identified all showed a large increase in receptor activation,
both in response to the agonist NECA and independent of a
ligand. This could suggest that the cysteine-rich cluster we
identified in our screen has a similar regulating role in
suppressing receptor activation in its basal state. The
cysteine occurrence analysis on all human class A GPCRs
revealed that the A2BR contains an exceptionally large
number of four cysteines in EL2, whereas most non-
olfactory class A GPCRs only contain one cysteine
(Fig. 8; see also an analysis by de Graaf et al. [28]). In
olfactory receptors, the cysteine occurrence is much higher,
which may be linked to metal ion binding [29].
In TM5, the mutated residues are found in a small cluster
of three residues at the bottom of the helix: I197
5.53,
V200
5.56, and Y202
5.58. From the crystal structure of the
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residues in TM5 have been indicated to play a role in
agonist and/or antagonist binding: M177
5.38,F 1 8 0
5.41,
N181
5.42, and F182
5.43 [5, 40]. The recently published
active structures in which NECA and adenosine are co-
crystallized, reveal that M177
5.38, N181
5.42 are directly
involved in the ligand binding pocket of these ribose-
containing agonists [7]. The residues identified in our
screen are located much lower in the helix and are therefore
unlikely to participate in the ligand binding pocket.
However, the large increase in agonist potency and
constitutive activity observed in our study implies that
these residues are essential in receptor activation.
CAMs in the adenosine A2BR
The fragments upstream and downstream of the investigated
fragment TM4-EL2-TM5 had been subjected to a random
mutagenesis screen in a similar manner in our laboratory [2,
3]. In Fig. 1, the ensemble of CAM residues identified in the
different studies is indicated ingray, fromwhich we conclude
that next to the described clusters in TM4, EL2, and TM5,
similar series of residues exist in TM3 and TM6. Even
though the screening set up in all three screens (ATG-KpnI,
TM4-EL2-TM5, and BglII-stop) was chosen such that both
CAMs and gain-of-function mutants would be selected, all
the identified mutant receptors displayed an increase in
constitutive activity. The levels of constitutive activity ranged
from a 1.5-fold change (F141L
4.61 and N36D
IL1)c o m p a r e d
with the wild-type receptor to an immense increase of 38-
fold for mutant receptor G135A
4.55/I197L
5.53/Y202N
5.58.
Interestingly, of all 41 residues identified in constitutively
active mutants of the A2BR, only four were actually involved
in binding of either adenosine or NECA at the corresponding
positions in the crystal structures of the A2ARp u b l i s h e db y
Lebon et al. [7] These corresponding residues in the A2BR
are: F173
EL2,V 2 5 0
6.51,N 2 5 4
6.55, and T257
6.58. The last
three, all residing in TM6, were identified in one particular
multiple mutant receptor; Q214L/I230N/V240M/V250M/
N254Y/T257S/K269stop (IL3/6.31/6.41/6.51/6.55/6.58/
EL3) [2]. The residue F173
EL2 (F168 in A2AR) directly
interacts with all the ligands co-crystallized with the A2AR
through a π-stacking contact. For the antagonist ZM241385,
the triazolotriazine ring interacts with the phenylalanine,
where in the agonists UK-432097, NECA, and adenosine, π-
stacking occurs with the adenine moiety. In the study
described here, the F173L
EL2 mutant receptor displayed a
large increase in potency for NECA. Mutating the
corresponding F168
EL2 in the A2AR into other aromatic
residues resulted in a moderate decrease in activation of the
receptor; mutation into an alanine virtually abolished
activation [40]. Assuming that the F173
EL2 in the A2BR
has a similar role in binding, a large hydrophobic residue
might be required at this position, however removing the
aromatic side chain can even improve agonist access to the
binding pocket.
Many of the CAMs in our studies only have one or two
amino acid changes, indicating that quite subtle changes
can lead to a large impact on the receptor activation
mechanism and that these residues are not necessarily
directly involved in either ligand binding or G protein
coupling.
Residues F141
4.61, C167
EL2, and Y202
5.58
The amino acids F141
4.61, C167
EL2, an Y202
5.58 were
identified multiple times in the screen. This may indicate
that these residues are of particular importance in the
activation mechanism of the A2BR. Position F141
4.61 has
been reported previously as being involved in affinity and
potency changes. The polymorphic variant M172I
4.61,
located at the corresponding position in the serotonin 1A
receptor, displayed a 3-fold increase in agonist potency
[41]. In another subtype of serotonin receptors, 5HT1B,
substitution of the amino acid F185
4.61 by an alanine
increased the affinities for several agonists [42]. In the
study described here, mutating F141
4.61 to a leucine
resulted in a 25-fold increase in potency for NECA and a
5-fold increase in potency in response to the non-ribose
agonist BAY 60-6583 (Fig. 2, Table 1). Radioligand binding
studies revealed that affinity for both agonists was also
largely increased (Table 2). The residue is located at the
onset of EL2, pointing outwards (Fig. 7b). Although the
residue is at great distance from the putative binding pocket
of both NECA and BAY 60-6583, it is firmly involved in
both agonist activation and binding [43]. The location of
the residue does suggest a main role in positioning EL2,
and could therefore be indirectly involved in shaping the
entry of the agonist binding pocket.
Mutant receptor C167S
EL2 showed an increase of ca. 16-
fold in potency for the adenosine derivative NECA as well
as a constitutive activity that was 6-fold higher compared
with wild type (Table 1). Radioligand binding experiments
also revealed an increase in binding affinity for the
adenosine derivative NECA (Fig. 5). Interestingly, when
we activated the C167S
EL2 mutant with BAY 60-6583, a
structurally different agonist that lacks a ribose moiety, only
a 2-fold change in potency was observed and affinity
remained unchanged compared with wild type (Fig. 5;
Table 1). Residue C167
EL2 is likely able to form a non-
conserved disulfide bridge with a cysteine in EL1 in the
A2BR as seen in the crystal structure of the closest family
member, the A2AR[ 3] (Fig. 1). Our results indicate that the
putative disulfide bridge between C167
EL2 and C72
EL1 is
important for ribose agonist binding and activation, but less
so for non-ribose agonists. Schiedel et al. recently
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residues present in EL2 of the A2BR. Mutating C167
EL2 to
a serine resulted in a 2.5-fold increase in potency for BAY
60-6583, similar to our observations, although the response
to NECA of this mutant receptor was less pronounced in
their study [44]. The tyrosine at position 202
5.58 is highly
conserved among class A GPCRs (88%) and there are
several studies reporting this position as being important in
receptor activation and G protein signaling. A somatic
mutation in the thyroid-stimulating hormone receptor
involved in toxic adenoma, Y601N
5.58, showed increased
levels of constitutive activity, but was unable to couple to
Gq/11 [45]. Very recently, Sansuk et al. proposed that
movement at the extracellular side of TM5 is transduced as
a set of structural rearrangements toward the intracellular
side, so enabling interactions of Y5.58 with R3.50 in the
cytoplasmic side of the receptor [46]. When comparing the
inactive and active structures of the adenosine A2AR, we
learned that Y5.58 (Y197 in the A2AR) displays a large
rotameric shift upon activation. While in the ZM241385-
bound, inactive structure the conserved Y197
5.58 is located
in between TM3 and TM6, this residue moves outward in
the agonist-bound forms allowing TM5 to shift toward
TM6. As a result, the intracellular ends of TM5 and TM6
move closer together in the active structures compared
with the inactive structure, enabling access of the G
protein [5–7]. In our screen, mutant Y202S
5.58 showed a
13-fold increase in constitutive activity that could be
reduced to wild-type levels in response to the inverse
agonist ZM241385 with an IC50 comparable to the wild-
type receptor, indicating that the mutation does not lock
the receptor in an active conformation [23, 24]( F i g .3).
NECA potency was 11-fold increased, but maximal
activation levels could not be reached, suggesting a
decrease in coupling to and signaling through the G
protein (Fig. 2;T a b l e1).
Concluding remarks
By applying an unbiased random mutagenesis approach
with subsequent phenotype screening in a robust yeast
system, we identified three hotspots in the A2BR that show
a vast increase in both spontaneous and agonist-induced
activity. None of the identified residues within these three
clusters are part of the ligand binding pocket, yet, they are
involved in agonist potency and affinity. Some of the
identified residues, like C167
EL2, most likely contribute to
an A2BR-specific response to agonists. Others, such as
F141
4.61 and Y202
5.58, might be part of a general activation
mechanism for class A GPCRs. An overview of all the
CAMs in the A2BR identified so far, indicates that there are
several clusters of amino acids responsible for maintaining
the subtle equilibrium that exist between the active
conformation R
* and the inactive conformation R of the
receptor and that these residues are not necessarily directly
involved in either ligand binding or G protein coupling. In
more general terms, the results presented here could be of
great use in unraveling the molecular details of GPCR
activation.
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